Literature DB >> 32423953

Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018.

Marya D Zilberberg1, Brian H Nathanson2, Kate Sulham3, Andrew F Shorr4.   

Abstract

In the face of increasing rates of antimicrobial resistance in complicated urinary tract infections (cUTIs), clinicians need to understand cross-resistance patterns among commonly encountered pathogens. We performed a multicenter, retrospective cohort study in the Premier database of approximately 180 hospitals, from 2013 to 2018. Using an ICD-9/10-based algorithm, we identified all adult patients hospitalized with cUTIs and included those with a positive blood or urine culture. We examined the microbiology and susceptibilities to common cUTI antimicrobials (3rd-generation cephalosporin [C3], fluoroquinolones [FQ], trimethoprim-sulfamethoxazole [TMP/SMZ], fosfomycin [FFM], and nitrofurantoin [NFT]) singly and in groups of two. Among 28,057 organisms from 23,331 patients, the 3 most common pathogens were Escherichia coli (41.0%; C3r, 15.1%), Klebsiella pneumoniae (12.1%; C3r, 13.2%), and Pseudomonas aeruginosa (11.0%; C3r, 12.0%). E. coli was most frequently resistant to FQ (43.5%) and least to NFT (6.7%). K. pneumoniae was most frequently resistant to NFT (60.8%) and least to FFM (0.1%). P. aeruginosa was most frequently resistant to FQ (34.4%) and least to TMP/SMZ (4.2%). Of the C3r E. coli isolates, 87.1% were also FQr, 63.7% were TMP/SMZr, and 13.3% were NFTr C3r K. pneumoniae isolates had a 76.5% chance of being FQr, 78.1% were TMP/SMZr, and 77.6% were NFTr C3r P. aeruginosa coexisted with FQr in 47.3%, TMP/SMZr in 18.9%, and NFTr in 28.7%. Among the most common pathogens isolated from hospitalized patients with cUTIs, the rates of single resistance to common treatments and of cross-resistance to these regimens are substantial. Knowing the patterns of cross-resistance may help clinicians tailor empirical therapy more precisely.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antimicrobial resistance; complicated UTI; cross-resistance; hospitalization

Mesh:

Substances:

Year:  2020        PMID: 32423953      PMCID: PMC7526848          DOI: 10.1128/AAC.00346-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

2.  The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis.

Authors:  Tara Lagu; Mihaela S Stefan; Sarah Haessler; Thomas L Higgins; Michael B Rothberg; Brian H Nathanson; Nicholas S Hannon; Jay S Steingrub; Peter K Lindenauer
Journal:  J Hosp Med       Date:  2014-04-09       Impact factor: 2.960

3.  Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.

Authors:  R Raz; B Chazan; Y Kennes; R Colodner; E Rottensterich; M Dan; I Lavi; W Stamm
Journal:  Clin Infect Dis       Date:  2002-04-04       Impact factor: 9.079

4.  In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.

Authors:  Guillermo V Sanchez; Ronald N Master; James A Karlowsky; Jose M Bordon
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Susceptibility of urinary tract bacteria to fosfomycin.

Authors:  Sofia Maraki; George Samonis; Petros I Rafailidis; Evridiki K Vouloumanou; Emmanuel Mavromanolakis; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

6.  Outcomes of patients with healthcare-associated pneumonia: worse disease or sicker patients?

Authors:  Michael B Rothberg; Sarah Haessler; Tara Lagu; Peter K Lindenauer; Penelope S Pekow; Aruna Priya; Daniel Skiest; Marya D Zilberberg
Journal:  Infect Control Hosp Epidemiol       Date:  2014-10       Impact factor: 3.254

7.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Cristina Vazquez-Guillamet; Marin H Kollef
Journal:  Crit Care       Date:  2014-11-21       Impact factor: 9.097

8.  30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  Antimicrob Resist Infect Control       Date:  2017-12-06       Impact factor: 4.887

9.  Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Weihong Fan; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2017-04-17       Impact factor: 3.090

10.  Using highly detailed administrative data to predict pneumonia mortality.

Authors:  Michael B Rothberg; Penelope S Pekow; Aruna Priya; Marya D Zilberberg; Raquel Belforti; Daniel Skiest; Tara Lagu; Thomas L Higgins; Peter K Lindenauer
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more
  10 in total

1.  Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing.

Authors:  Paul H Edelstein; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Reply to Edelstein and Humphries, "Improbable Results of Urine Isolate Antimicrobial Susceptibility Testing".

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Andrew F Shorr
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

4.  Glycosuria Alters Uropathogenic Escherichia coli Global Gene Expression and Virulence.

Authors:  Md Jahirul Islam; Kamal Bagale; Preeti P John; Zachary Kurtz; Ritwij Kulkarni
Journal:  mSphere       Date:  2022-04-28       Impact factor: 5.029

5.  Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2021-02-08       Impact factor: 3.090

6.  Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Andrew F Shorr
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

7.  Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016-2018.

Authors:  Marya D Zilberberg; Brian H Nathanson; Kate Sulham; Andrew F Shorr
Journal:  J Am Coll Emerg Physicians Open       Date:  2022-03-17

8.  Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014-2019.

Authors:  Marya D Zilberberg; Brian H Nathanson; Laura A Puzniak; Noah W D Zilberberg; Andrew F Shorr
Journal:  Crit Care Explor       Date:  2022-04-07

9.  Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections.

Authors:  Thomas P Lodise; Janna Manjelievskaia; Elizabeth Hoit Marchlewicz; Mauricio Rodriguez
Journal:  Open Forum Infect Dis       Date:  2022-06-20       Impact factor: 4.423

10.  Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States.

Authors:  Thomas P Lodise; Teena Chopra; Brian H Nathanson; Katherine Sulham; Mauricio Rodriguez
Journal:  Open Forum Infect Dis       Date:  2022-06-24       Impact factor: 4.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.